Annual Report 2025-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bansisons Tea Industries (now renamed Novyra Pharmachem Limited) has filed its 39th Annual Report along with the AGM notice for June 25, 2026. The key proposal is a major Scheme of Capital Reduction, reducing paid-up share capital from Rs.6.33 crore (63.30 lakh shares) to Rs.90.43 lakh (9.04 lakh shares), effectively cancelling 85.71% of equity shares (54.25 lakh shares). The company also plans to write off Rs.5.43 crore out of Rs.5.71 crore in accumulated losses to clean up its balance sheet. Additionally, Mr. Anilkumar Amreliya (appointed as Executive Director on 06/02/2026) is being regularized and proposed as Managing Director for 5 years at a salary of Rs.11,000 per month. The AGM will be held via video conferencing.
For existing shareholders, this is a significant value-eroding event: 85.71% of their shareholding will be cancelled/extinguished, meaning each shareholder's stake will be reduced to roughly 14.29% of what it was, while the share price may not adjust proportionally. The capital reduction is aimed at wiping out accumulated losses of Rs.5.71 crore, signaling persistent unprofitability. The stock price is likely to react negatively when the NCLT-approved reduction takes effect.